Re­cent­ly stung by AAV, Sarep­ta dives a lit­tle deep­er in­to non-vi­ral de­liv­ery with newest li­cens­ing pact

The use of ade­no-as­so­ci­at­ed virus­es (AAV) as de­liv­ery ve­hi­cles for gene ther­a­peu­tics has been rid­dled with safe­ty con­cerns for years — a fact Sarep­ta knows well …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER